hcov 229e anti spike antibody Search Results


229e  (Sino Biological)
94
Sino Biological 229e
(A) Bar dot plots show the level of IgG1 antibodies against non-coronaviruses (EBV, Flu, HSV1) in individuals who did not develop (no PASC, in blue) or developed neurological PASC (neuroPASC, in purple). MFI=Median Fluorescence Intensity. Mann-Whitney, ns= statistically not significant. (B) Heatmap indicates the average difference (%) of SARS-CoV-2 -specific (Spike, S1, S2, RBD and NC) and common Coronaviruses-specific <t>(229E,</t> OC43, NL63, HKU1) IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgM and IgA1, IgA2, binding capacity to FcγRs (2A, 2B, 3A, 3B), FcαR, between individuals with no PASC and with neuroPASC. Each column represents an antibody feature. Positive values (purple) indicate features enriched in no PASC, negative values (blue) indicate features enriched in neuroPASC, null values (white) indicate features equally present in both no PASC and neuroPASC. Common CoVs = other non-SARS-CoV-2 common Coronaviruses; NC= SARS-CoV-2 nucleocapsid; RBD= SARS-CoV-2 receptor binding domain. Mann-Whitney was used to define statistically significant differences at a univariate level between no PASC and neuroPASC, *p<0.01 or less. ( C-D ) Multivariate analysis of antibody signatures in individuals with neuroPASC and no PASC. Partial least square discriminant analysis (PLSDA) on LASSO-selected features was used to resolve antibody profiles in neuroPASC and no PASC. Dots represent individual samples (no PASC, blue; neuroPASC, red) across SARS-CoV-2 specific (Spike, S1, S2, RBD, NC), and common Coronaviruses (229E, OC43, NL63, HKU1) specific antibody features. Bar graph shows LV1 loadings of LASSO-selected features ranked by their Variable Importance in Projection (VIP). Features enriched in no PASC are in blue, features enriched in neuroPASC are in red. Ten-fold cross validation was performed, resulting in 84% cross validation accuracy (p<0.01). (E) Chord plots indicate the Spearman correlation coefficients between the LASSO-selected features enriched in no PASC (left) and in neuroPASC (right), and the non-LASSO selected antibody features across SARS-CoV-2 antigens (Spike, S1, S2, RBD, NC), and other common Coronaviruses antigens (229E, OC43, NL63, HKU1). Only coefficients >0.5 are plotted, p<0.01 after Benjamini-Hochberg correction for multiple comparisons. Positive values represent direct correlations, negative values represent inverse correlations (none of the features were inversely correlated with any other feature).
229e, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hcov+229e+anti+spike+antibody/Human+coronavirus+(HCoV-229E)+Spike+Protein/med_rxiv__2022__11__07__22282030-34-55-56
Average 94 stars, based on 1 article reviews
229e - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
hcov 229e spike protein  (Native Antigen Inc)
94
Native Antigen Inc hcov 229e spike protein
(A) Bar dot plots show the level of IgG1 antibodies against non-coronaviruses (EBV, Flu, HSV1) in individuals who did not develop (no PASC, in blue) or developed neurological PASC (neuroPASC, in purple). MFI=Median Fluorescence Intensity. Mann-Whitney, ns= statistically not significant. (B) Heatmap indicates the average difference (%) of SARS-CoV-2 -specific (Spike, S1, S2, RBD and NC) and common Coronaviruses-specific <t>(229E,</t> OC43, NL63, HKU1) IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgM and IgA1, IgA2, binding capacity to FcγRs (2A, 2B, 3A, 3B), FcαR, between individuals with no PASC and with neuroPASC. Each column represents an antibody feature. Positive values (purple) indicate features enriched in no PASC, negative values (blue) indicate features enriched in neuroPASC, null values (white) indicate features equally present in both no PASC and neuroPASC. Common CoVs = other non-SARS-CoV-2 common Coronaviruses; NC= SARS-CoV-2 nucleocapsid; RBD= SARS-CoV-2 receptor binding domain. Mann-Whitney was used to define statistically significant differences at a univariate level between no PASC and neuroPASC, *p<0.01 or less. ( C-D ) Multivariate analysis of antibody signatures in individuals with neuroPASC and no PASC. Partial least square discriminant analysis (PLSDA) on LASSO-selected features was used to resolve antibody profiles in neuroPASC and no PASC. Dots represent individual samples (no PASC, blue; neuroPASC, red) across SARS-CoV-2 specific (Spike, S1, S2, RBD, NC), and common Coronaviruses (229E, OC43, NL63, HKU1) specific antibody features. Bar graph shows LV1 loadings of LASSO-selected features ranked by their Variable Importance in Projection (VIP). Features enriched in no PASC are in blue, features enriched in neuroPASC are in red. Ten-fold cross validation was performed, resulting in 84% cross validation accuracy (p<0.01). (E) Chord plots indicate the Spearman correlation coefficients between the LASSO-selected features enriched in no PASC (left) and in neuroPASC (right), and the non-LASSO selected antibody features across SARS-CoV-2 antigens (Spike, S1, S2, RBD, NC), and other common Coronaviruses antigens (229E, OC43, NL63, HKU1). Only coefficients >0.5 are plotted, p<0.01 after Benjamini-Hochberg correction for multiple comparisons. Positive values represent direct correlations, negative values represent inverse correlations (none of the features were inversely correlated with any other feature).
Hcov 229e Spike Protein, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hcov+229e+anti+spike+antibody/Rabbit+IgG+Anti+HCoV-229E+Spike+(S1)+Polyclonal+Antibody/pm38754785-105-7-12
Average 94 stars, based on 1 article reviews
hcov 229e spike protein - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti-hcov-229e spike antibody  (TargetMol)
N/A
   Buy from Supplier
anti-coronavirus (hcov-nl63, hcov-229e) spike antibody  (TargetMol)
N/A
   Buy from Supplier

Image Search Results


(A) Bar dot plots show the level of IgG1 antibodies against non-coronaviruses (EBV, Flu, HSV1) in individuals who did not develop (no PASC, in blue) or developed neurological PASC (neuroPASC, in purple). MFI=Median Fluorescence Intensity. Mann-Whitney, ns= statistically not significant. (B) Heatmap indicates the average difference (%) of SARS-CoV-2 -specific (Spike, S1, S2, RBD and NC) and common Coronaviruses-specific (229E, OC43, NL63, HKU1) IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgM and IgA1, IgA2, binding capacity to FcγRs (2A, 2B, 3A, 3B), FcαR, between individuals with no PASC and with neuroPASC. Each column represents an antibody feature. Positive values (purple) indicate features enriched in no PASC, negative values (blue) indicate features enriched in neuroPASC, null values (white) indicate features equally present in both no PASC and neuroPASC. Common CoVs = other non-SARS-CoV-2 common Coronaviruses; NC= SARS-CoV-2 nucleocapsid; RBD= SARS-CoV-2 receptor binding domain. Mann-Whitney was used to define statistically significant differences at a univariate level between no PASC and neuroPASC, *p<0.01 or less. ( C-D ) Multivariate analysis of antibody signatures in individuals with neuroPASC and no PASC. Partial least square discriminant analysis (PLSDA) on LASSO-selected features was used to resolve antibody profiles in neuroPASC and no PASC. Dots represent individual samples (no PASC, blue; neuroPASC, red) across SARS-CoV-2 specific (Spike, S1, S2, RBD, NC), and common Coronaviruses (229E, OC43, NL63, HKU1) specific antibody features. Bar graph shows LV1 loadings of LASSO-selected features ranked by their Variable Importance in Projection (VIP). Features enriched in no PASC are in blue, features enriched in neuroPASC are in red. Ten-fold cross validation was performed, resulting in 84% cross validation accuracy (p<0.01). (E) Chord plots indicate the Spearman correlation coefficients between the LASSO-selected features enriched in no PASC (left) and in neuroPASC (right), and the non-LASSO selected antibody features across SARS-CoV-2 antigens (Spike, S1, S2, RBD, NC), and other common Coronaviruses antigens (229E, OC43, NL63, HKU1). Only coefficients >0.5 are plotted, p<0.01 after Benjamini-Hochberg correction for multiple comparisons. Positive values represent direct correlations, negative values represent inverse correlations (none of the features were inversely correlated with any other feature).

Journal: medRxiv

Article Title: Neurologic sequalae of COVID-19 are determined by immunologic imprinting from previous Coronaviruses

doi: 10.1101/2022.11.07.22282030

Figure Lengend Snippet: (A) Bar dot plots show the level of IgG1 antibodies against non-coronaviruses (EBV, Flu, HSV1) in individuals who did not develop (no PASC, in blue) or developed neurological PASC (neuroPASC, in purple). MFI=Median Fluorescence Intensity. Mann-Whitney, ns= statistically not significant. (B) Heatmap indicates the average difference (%) of SARS-CoV-2 -specific (Spike, S1, S2, RBD and NC) and common Coronaviruses-specific (229E, OC43, NL63, HKU1) IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgM and IgA1, IgA2, binding capacity to FcγRs (2A, 2B, 3A, 3B), FcαR, between individuals with no PASC and with neuroPASC. Each column represents an antibody feature. Positive values (purple) indicate features enriched in no PASC, negative values (blue) indicate features enriched in neuroPASC, null values (white) indicate features equally present in both no PASC and neuroPASC. Common CoVs = other non-SARS-CoV-2 common Coronaviruses; NC= SARS-CoV-2 nucleocapsid; RBD= SARS-CoV-2 receptor binding domain. Mann-Whitney was used to define statistically significant differences at a univariate level between no PASC and neuroPASC, *p<0.01 or less. ( C-D ) Multivariate analysis of antibody signatures in individuals with neuroPASC and no PASC. Partial least square discriminant analysis (PLSDA) on LASSO-selected features was used to resolve antibody profiles in neuroPASC and no PASC. Dots represent individual samples (no PASC, blue; neuroPASC, red) across SARS-CoV-2 specific (Spike, S1, S2, RBD, NC), and common Coronaviruses (229E, OC43, NL63, HKU1) specific antibody features. Bar graph shows LV1 loadings of LASSO-selected features ranked by their Variable Importance in Projection (VIP). Features enriched in no PASC are in blue, features enriched in neuroPASC are in red. Ten-fold cross validation was performed, resulting in 84% cross validation accuracy (p<0.01). (E) Chord plots indicate the Spearman correlation coefficients between the LASSO-selected features enriched in no PASC (left) and in neuroPASC (right), and the non-LASSO selected antibody features across SARS-CoV-2 antigens (Spike, S1, S2, RBD, NC), and other common Coronaviruses antigens (229E, OC43, NL63, HKU1). Only coefficients >0.5 are plotted, p<0.01 after Benjamini-Hochberg correction for multiple comparisons. Positive values represent direct correlations, negative values represent inverse correlations (none of the features were inversely correlated with any other feature).

Article Snippet: The antibody responses were assessed against 5 different SARS-CoV-2 antigens, including Spike WT (Sino Biological 40589-V08H4), RBD WT (Sino Biological 40592-V08H), S1 WT (Sino Biological 40591-V08H), S2 WT (Sino Biological 40590-V08B) and Nucleocapsid (Sino Biological 40588-V08B), as well as 4 non-SARS-CoV-2 coronaviruses, including HCoV-OC43 (Sino Biological 40607-V08B), -HKU1 (Sino Biological 40606-V08B), -NL63 (Sino Biological 40604-V08B), -229E (Sino Biological 40605-V08B).

Techniques: Fluorescence, MANN-WHITNEY, Binding Assay

(A) Heatmap indicating the average difference (%) of antibody responses to SARS-CoV-2 (Spike, S1, S2, RBD and NC), other common Coronaviruses (229E, OC43, NL63, HKU1) and non-coronaviruses (EBV, Flu, HHV1), including IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgM and IgA, binding capacity to FcγR (2A, 2B, 3A, 3B) and FcαR, between serum and CSF from individuals with neuroPASC. Positive values (purple) indicate features enriched in serum, negative values (blue) indicate features enriched in CSF, null values (white) indicate features equally present in both serum and CSF. There were no features enriched in CSF. Common CoVs = other non-SARS-CoV-2 common Coronaviruses (229E, OC43, NL63, HKU1); NC= nucleocapsid; RBD= receptor binding domain (B-C) Multivariate analyses of antibody signatures in serum and CSF from individuals with neuroPASC. Multilevel partial least square discriminant analysis (M-PLSDA) on LASSO-selected features was used to resolve antibody profiles in serum:CSF pairs. Dots represent individual samples (serum, blue; CSF, purple) across SARS-CoV-2 antigens (Spike, S1, S2, RBD, NC), and common Coronaviruses (229E, OC43, NL63, HKU1). Bar graph shows LV1 loadings of LASSO-selected features ranked by their Variable Importance in Projection (VIP). Features enriched in serum are in purple, no features were enriched in CSF. Ten-fold cross validation was performed, resulting in 100% cross validation accuracy (p<0.01). (D-E) Bar dot plots indicate CSF to serum ratios of IgG1, FcγR (2A, 2B, 3A) and FcαR binding capacity for SARS-CoV-2 (Spike, S1, S2, RBD, NC antigens combined) and other common Coronaviruses (229E, OC43, NL63, HKU1 combined) antibodies in individuals with neuroPASC. Mann-Whitney, *p<0.05, ***p<0.001 ****p<0.0001. CoV=common Coronaviruses; NC= nucleocapsid; RBD= receptor binding domain (F) Bar dot plots show the binding capacity of antibodies to the neonatal Fc receptor (FcRn) of serum and CSF SARS-CoV-2 antibodies targeting different antigens (Spike, S1, S2, RDB, NC) in individuals with neuroPASC. Mann-Whitney, *p<0.05, **p<0.01, ***p<0.001 ****p<0.0001. MFI=Median Fluorescence Intensity; NC=nucleocapsid; RBD=receptor binding domain (G) Bar dot plots indicate the FcRn binding capacity of serum and CSF SARS-CoV-2 antibodies (Spike, S1, S2, RBD, NC, combined), compared to common Coronaviruses (229E, OC43, NL63, HKU1 combined) and non-coronaviruses (EBV, Flu, HSV1 combined). Kruskal Wallis test, Dunn’s correction for multiple comparisons. **p<0.01, ****p<0.0001. MFI=Median Fluorescence Intensity; NC= nucleocapsid; RBD= receptor binding domain

Journal: medRxiv

Article Title: Neurologic sequalae of COVID-19 are determined by immunologic imprinting from previous Coronaviruses

doi: 10.1101/2022.11.07.22282030

Figure Lengend Snippet: (A) Heatmap indicating the average difference (%) of antibody responses to SARS-CoV-2 (Spike, S1, S2, RBD and NC), other common Coronaviruses (229E, OC43, NL63, HKU1) and non-coronaviruses (EBV, Flu, HHV1), including IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgM and IgA, binding capacity to FcγR (2A, 2B, 3A, 3B) and FcαR, between serum and CSF from individuals with neuroPASC. Positive values (purple) indicate features enriched in serum, negative values (blue) indicate features enriched in CSF, null values (white) indicate features equally present in both serum and CSF. There were no features enriched in CSF. Common CoVs = other non-SARS-CoV-2 common Coronaviruses (229E, OC43, NL63, HKU1); NC= nucleocapsid; RBD= receptor binding domain (B-C) Multivariate analyses of antibody signatures in serum and CSF from individuals with neuroPASC. Multilevel partial least square discriminant analysis (M-PLSDA) on LASSO-selected features was used to resolve antibody profiles in serum:CSF pairs. Dots represent individual samples (serum, blue; CSF, purple) across SARS-CoV-2 antigens (Spike, S1, S2, RBD, NC), and common Coronaviruses (229E, OC43, NL63, HKU1). Bar graph shows LV1 loadings of LASSO-selected features ranked by their Variable Importance in Projection (VIP). Features enriched in serum are in purple, no features were enriched in CSF. Ten-fold cross validation was performed, resulting in 100% cross validation accuracy (p<0.01). (D-E) Bar dot plots indicate CSF to serum ratios of IgG1, FcγR (2A, 2B, 3A) and FcαR binding capacity for SARS-CoV-2 (Spike, S1, S2, RBD, NC antigens combined) and other common Coronaviruses (229E, OC43, NL63, HKU1 combined) antibodies in individuals with neuroPASC. Mann-Whitney, *p<0.05, ***p<0.001 ****p<0.0001. CoV=common Coronaviruses; NC= nucleocapsid; RBD= receptor binding domain (F) Bar dot plots show the binding capacity of antibodies to the neonatal Fc receptor (FcRn) of serum and CSF SARS-CoV-2 antibodies targeting different antigens (Spike, S1, S2, RDB, NC) in individuals with neuroPASC. Mann-Whitney, *p<0.05, **p<0.01, ***p<0.001 ****p<0.0001. MFI=Median Fluorescence Intensity; NC=nucleocapsid; RBD=receptor binding domain (G) Bar dot plots indicate the FcRn binding capacity of serum and CSF SARS-CoV-2 antibodies (Spike, S1, S2, RBD, NC, combined), compared to common Coronaviruses (229E, OC43, NL63, HKU1 combined) and non-coronaviruses (EBV, Flu, HSV1 combined). Kruskal Wallis test, Dunn’s correction for multiple comparisons. **p<0.01, ****p<0.0001. MFI=Median Fluorescence Intensity; NC= nucleocapsid; RBD= receptor binding domain

Article Snippet: The antibody responses were assessed against 5 different SARS-CoV-2 antigens, including Spike WT (Sino Biological 40589-V08H4), RBD WT (Sino Biological 40592-V08H), S1 WT (Sino Biological 40591-V08H), S2 WT (Sino Biological 40590-V08B) and Nucleocapsid (Sino Biological 40588-V08B), as well as 4 non-SARS-CoV-2 coronaviruses, including HCoV-OC43 (Sino Biological 40607-V08B), -HKU1 (Sino Biological 40606-V08B), -NL63 (Sino Biological 40604-V08B), -229E (Sino Biological 40605-V08B).

Techniques: Binding Assay, MANN-WHITNEY, Fluorescence

(A) The radial plots indicate the levels of IgG1 and FcγR2A binding capacity of SARS-CoV-2 antibodies (Spike, S1, S2, RBD, upper half circle) and common Coronaviruses (229E, OC43, NL63, lower half circle) in individuals with neuroPASC, divided into those with good versus poor outcome. Each sector represents a z-scored antibody feature. RBD=receptor binding domain (B-C) Volcano plots showing the correlation of each SARS-CoV-2 and common Coronaviruses (229E, OC43, NL63, HKU1)-antibody feature with modified Rankin Scale (mRS). Spearman correlation coefficients are indicated in the x-axis (positive correlation on the right, red; negative correlation on the left, blue), and the statistical significance is indicated in the y-axis (-log10[p-values]). Values above black dashed line indicate statistically significant correlations (p adjusted value<0.01, Benjamini-Hochberg correction for multiple comparisons). Negative correlations, indicating good outcome, were identified with serum antibodies (left graph, in blue), whereas negative correlations, indicating poor outcome, were identified with CSF antibody profiles (right graph, in red).

Journal: medRxiv

Article Title: Neurologic sequalae of COVID-19 are determined by immunologic imprinting from previous Coronaviruses

doi: 10.1101/2022.11.07.22282030

Figure Lengend Snippet: (A) The radial plots indicate the levels of IgG1 and FcγR2A binding capacity of SARS-CoV-2 antibodies (Spike, S1, S2, RBD, upper half circle) and common Coronaviruses (229E, OC43, NL63, lower half circle) in individuals with neuroPASC, divided into those with good versus poor outcome. Each sector represents a z-scored antibody feature. RBD=receptor binding domain (B-C) Volcano plots showing the correlation of each SARS-CoV-2 and common Coronaviruses (229E, OC43, NL63, HKU1)-antibody feature with modified Rankin Scale (mRS). Spearman correlation coefficients are indicated in the x-axis (positive correlation on the right, red; negative correlation on the left, blue), and the statistical significance is indicated in the y-axis (-log10[p-values]). Values above black dashed line indicate statistically significant correlations (p adjusted value<0.01, Benjamini-Hochberg correction for multiple comparisons). Negative correlations, indicating good outcome, were identified with serum antibodies (left graph, in blue), whereas negative correlations, indicating poor outcome, were identified with CSF antibody profiles (right graph, in red).

Article Snippet: The antibody responses were assessed against 5 different SARS-CoV-2 antigens, including Spike WT (Sino Biological 40589-V08H4), RBD WT (Sino Biological 40592-V08H), S1 WT (Sino Biological 40591-V08H), S2 WT (Sino Biological 40590-V08B) and Nucleocapsid (Sino Biological 40588-V08B), as well as 4 non-SARS-CoV-2 coronaviruses, including HCoV-OC43 (Sino Biological 40607-V08B), -HKU1 (Sino Biological 40606-V08B), -NL63 (Sino Biological 40604-V08B), -229E (Sino Biological 40605-V08B).

Techniques: Binding Assay, Modification